Cargando…

Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach

Detalles Bibliográficos
Autores principales:	Alqahtani, Saleh A., Colombo, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607112/ https://www.ncbi.nlm.nih.gov/pubmed/33178787 http://dx.doi.org/10.21037/atm-2020-79

Ejemplares similares

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
por: Horger, Marius, et al.
Publicado: (2009)

Cardiac arrest - has the time of MRI come?
por: Galanaud, Damien, et al.
Publicado: (2010)

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
por: Adjibade, Pauline, et al.
Publicado: (2015)

Early start and stop of biologics: has the time come?
por: van Vollenhoven, Ronald F, et al.
Publicado: (2014)

A targeted extracorporeal therapy for endotoxemia: the time has come
por: Kellum, John A
Publicado: (2007)

Including vaccinations in the scope of dental practice: The time has come
por: Villa, Alessandro, et al.
Publicado: (2021)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Developing Supportive Care Services for Patients with Kidney Failure: An Idea Whose Time Has Come
por: Jha, Vivekanand
Publicado: (2021)

Addressing physician stress, burnout, and compassion fatigue: the time has come
por: Rosenstein, Alan H
Publicado: (2013)

At-home infectious disease testing: An idea whose time has come
por: Adalja, Amesh A.
Publicado: (2022)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Defining and measuring gender: A social determinant of health whose time has come
por: Phillips, Susan P
Publicado: (2005)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Automated anaesthesia record system - Expensive toy or a change whose time has come?
por: Shinde, Hemant
Publicado: (2019)

The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients
por: Schneider, Christopher, et al.
Publicado: (2018)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits
por: Mohanta, Sarajo Kumar, et al.
Publicado: (2022)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2020)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro
por: Schoen, Leonie F., et al.
Publicado: (2022)

Developing a personalized treatment model based on molecular biomarkers and imaging in breast cancer: Has the time come?
por: Choudhury, Partha
Publicado: (2016)

Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy
por: Shao, Mingyang, et al.
Publicado: (2023)

Telehealth’s Time Has Come
por: Waldrop, Julee B.
Publicado: (2020)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
por: Musso, Orlando, et al.
Publicado: (2019)

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells
por: Schult, Catrin, et al.
Publicado: (2010)

Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model
por: MURAKAMI, MASAHIRO, et al.
Publicado: (2013)

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms
por: Chen, Jiang, et al.
Publicado: (2020)

Improving Global Outcomes in Cervical Cancer: The Time Has Come for International Federation of Gynecology and Obstetrics Staging to Formally Incorporate Advanced Imaging
por: Jolly, Shruti, et al.
Publicado: (2017)

The Time has Come for All States to Measure Racial Discrimination: A Call to Action for the Pregnancy Risk Assessment Monitoring System (PRAMS)
por: Almeida, Joanna, et al.
Publicado: (2021)

The Time Has Come; One Year Has Passed
por: Heidary, Fatemeh, et al.
Publicado: (2013)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
por: Oranratnachai, Songporn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhof83jv93ssfpd11ncqqiaju4